New Ray Medicine International Holding (HKSE:06108) Total Inventories : HK$31.17 Mil (As of Dec. 2023)

View and export this data going back to 2013. Start your Free Trial

What is New Ray Medicine International Holding Total Inventories?

New Ray Medicine International Holding's total inventories for the quarter that ended in Dec. 2023 was HK$31.17 Mil. New Ray Medicine International Holding's average total inventories from the quarter that ended in Jun. 2023 to the quarter that ended in Dec. 2023 was HK$20.92 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. New Ray Medicine International Holding's Net-Net Working Capital per share for the quarter that ended in Dec. 2023 was HK$0.11.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year. New Ray Medicine International Holding's Inventory Turnover for the quarter that ended in Dec. 2023 was -1.37.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

New Ray Medicine International Holding Total Inventories Historical Data

The historical data trend for New Ray Medicine International Holding's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

New Ray Medicine International Holding Total Inventories Chart

New Ray Medicine International Holding Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Inventories

Get a 7-Day Free Trial

0.79

60.79

125.31

35.23

31.17

New Ray Medicine International Holding Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Total Inventories	Get a 7-Day Free Trial															125.31	68.08	35.23	10.66	31.17

New Ray Medicine International Holding Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.

New Ray Medicine International Holding (HKSE:06108) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

New Ray Medicine International Holding's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2023 is

	Net-Net Working Capital Per Share (Q: Dec. 2023 )
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(103.954	+	0.75 * 110.104	+	0.5 * 31.167	-	11.35
-	0	-	0)	/	1671.85
=	0.11

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

New Ray Medicine International Holding's Days Inventory for the six months ended in Dec. 2023 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Dec. 2023 )	/	Cost of Goods Sold (Q: Dec. 2023 )	*	Days in Period
	=	20.9155	/	-28.664	*	365 / 2
	=

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

New Ray Medicine International Holding's Inventory Turnover for the quarter that ended in Dec. 2023 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Dec. 2023 )	/	Average Total Inventories (Q: Dec. 2023 )
	=	-28.664	/	20.9155
	=	-1.37

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

New Ray Medicine International Holding's Inventory to Revenue for the quarter that ended in Dec. 2023 is calculated as

Inventory-to-Revenue	=	Average Total Inventories (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	20.9155	/	-22.885
	=

Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.

New Ray Medicine International Holding Total Inventories Related Terms

Thank you for viewing the detailed overview of New Ray Medicine International Holding's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.

New Ray Medicine International Holding (HKSE:06108) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » New Ray Medicine International Holding Ltd (HKSE:06108) » Definitions » Total Inventories

Comparable Companies

Traded in Other Exchanges

N/A

Address

19 Dangui Road, B-C, 37th Floor, Dikai International Center, Hangzhou, CHN

Website

http://www.newraymedicine.com

New Ray Medicine International Holding Ltd is engaged in the trading of pharmaceutical products in the People's Republic of China. The company's segments include Distribution and trading of pharmaceutical products and Provision of marketing and promotion services. Distribution and trading of pharmaceutical products consist of Injection drugs, Capsules and Granule drugs, Tablet drugs and Other Drugs. It generates a majority of its revenue from the distribution of Injection Drugs.

Executives

Dai Xiaosong
Eagle Amber Holdings Limited
Chu Xueping	2201 Interest of corporation controlled by you
Qian Shenglei	2101 Beneficial owner
Zhang Jiang	2201 Interest of corporation controlled by you
Yang Fang	2202 Interest of your spouse
Zhou Ling	2101 Beneficial owner

New Ray Medicine International Holding (HKSE:06108) Headlines

No Headlines